|
|
Volumn 89, Issue 8, 2010, Pages 821-822
|
|
Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BORTEZOMIB;
CYCLOPHOSPHAMIDE;
DEXAMETHASONE;
GRANULOCYTE COLONY STIMULATING FACTOR;
MELPHALAN;
VORICONAZOLE;
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
PYRAZINE DERIVATIVE;
ACUTE GRAFT REJECTION;
ADULT;
AUTOGRAFT;
AUTOLOGOUS STEM CELL TRANSPLANTATION;
CANCER COMBINATION CHEMOTHERAPY;
CANCER REGRESSION;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG TOLERABILITY;
FATIGUE;
FEBRILE NEUTROPENIA;
FOLLOW UP;
FUNCTIONAL STATUS;
GASTROINTESTINAL SYMPTOM;
HUMAN;
KIDNEY FAILURE;
KIDNEY GRAFT REJECTION;
LETTER;
LOW DRUG DOSE;
MALE;
MUCOSA INFLAMMATION;
MULTIPLE CYCLE TREATMENT;
MULTIPLE MYELOMA;
MYCOSIS;
PERIPHERAL NEUROPATHY;
PRIMARY HEALTH CARE;
PRIORITY JOURNAL;
RENAL REPLACEMENT THERAPY;
STEM CELL MOBILIZATION;
SYMPTOMATOLOGY;
TREATMENT DURATION;
TREATMENT PLANNING;
CHRONIC KIDNEY FAILURE;
MIDDLE AGED;
TREATMENT OUTCOME;
ADULT;
ANTINEOPLASTIC AGENTS;
BORONIC ACIDS;
HUMANS;
KIDNEY FAILURE, CHRONIC;
MALE;
MIDDLE AGED;
MULTIPLE MYELOMA;
PYRAZINES;
TREATMENT OUTCOME;
|
|
EID: 77954679892
PISSN: 09395555
EISSN: None
Source Type: Journal
DOI: 10.1007/s00277-009-0867-7 Document Type: Letter |
|
Times cited : (4)
|
|
References (5)
|
